Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
AOL,
Teprotumumab (TEPEZZA®) is the first FDA-approved medicine for TED, an autoimmune condition that can cause eye bulging…
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
BioSpace,
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study…
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Weekly Voice,
Primary and Key Secondary Endpoints Met -- 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study…
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA(TM) IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Stockwatch,
PR Newswire THOUSAND OAKS, Calif., April 6, 2026 Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly…